Ajanta Pharma block deal 2026: 2.8% stake for ₹1,024 cr

Overview of the Ajanta Pharma block deal

Ajanta Pharma Ltd. saw a large secondary transaction on Tuesday, June 9, 2026, after a promoter-group entity reduced its holding through market sales. Exchange data showed the selling entity was Ravi Agrawal Trust, linked to the company’s promoters. The trust sold 34.5 lakh equity shares at an average price of ₹2,968 per share. The sale was valued at around ₹1,024 crore, making it one of the larger pharma block deals of the day. Domestic institutional investors, led by mutual funds, were the key buyers for the offering. The trades were reported through NSE block deal and exchange disclosures referenced in the update.

What was sold, and at what price

As per the disclosed details, Ravi Agrawal Trust divested 34,50,000 shares of Ajanta Pharma. The sale represented about a 2.76% to 2.8% stake in the company, depending on the data cut cited in the reports. The execution price for the block was ₹2,968 per share. One update noted the deal price was at a marginal discount of 0.03% to the previous day’s closing price. The total consideration was reported at approximately ₹1,023.96 crore to ₹1,024 crore across the different summaries. The transaction was described as being executed via open market transactions and also referenced as a block deal in the exchange data.

How the promoter entity’s holding changed

Following the sale, Ravi Agrawal Trust’s ownership in Ajanta Pharma reduced materially. The disclosed before-and-after holding for the trust was 13.00% prior to the transaction and 10.24% after the sale. The disclosure also stated the sale was made under SEBI regulatory reporting requirements for promoter group transactions. Separately, a shareholding snapshot cited promoter holding at 66.25% for the March 2026 quarter. Taken together, the disclosed data points indicate the sale was a partial monetisation by one promoter-linked trust rather than a change in the company’s equity capital base.

Who bought the shares

The buying side was anchored by domestic mutual funds. Kotak Mahindra Mutual Fund acquired 21.02 lakh shares, while Aditya Birla Sun Life Mutual Fund purchased 13.48 lakh shares. Both purchases were reported at the same average price of ₹2,968 per share. In value terms, the Kotak acquisition was cited at around ₹624 crore, and the Aditya Birla Sun Life purchase at about ₹400 crore. Another summary also characterised the purchases as equivalent to roughly a 1.7% stake for Kotak and a 1.1% stake for Aditya Birla Sun Life. The buyer list in the update supports the view that institutional demand was sufficient to absorb the promoter selling in a single session.

Ajanta Pharma stock move on the day

The stock was trading higher after the block deal details circulated. At 10:21 am IST, Ajanta Pharma was quoted at ₹3,063.60, up 1.54% for the day. The stock opened at ₹3,058.80 and hit an intraday high of ₹3,070. The previous close was ₹3,017.20, as cited in the market update. The block deal price of ₹2,968 was below the live traded price at the time, highlighting that the negotiated transaction cleared at a level different from the subsequent intraday market quote.

Key figures at a glance

Capital structure details disclosed alongside

The update also carried specifics on Ajanta Pharma’s equity base. The company’s equity share capital was stated as ₹24,98,71,248, comprising 12,49,35,624 shares of face value ₹2 each. This provides context for the percentage stake calculations mentioned in the selling disclosure. The transaction itself was described as a sale of existing shares by a promoter-group trust and not as any issuance of new equity by the company.

Other promoter-group disclosure mentioned

Alongside the block deal coverage, the text referenced a separate promoter-related action involving a pledge. It stated that Aayush Agrawal, trustee of Aayush Agrawal Trust, pledged 28,55,925 shares representing 2.29% of Ajanta Pharma to CTL Trusteeship Limited for a new loan. This pledge disclosure is distinct from the June 9 sale by Ravi Agrawal Trust, but it adds to the broader picture of promoter-group financial actions disclosed around the same period.

Context from prior promoter selling

The coverage also pointed to a prior instance of promoter selling. It noted that in December 2022, the promoters, including Ravi Agrawal Trust and Aayush Agrawal Trust, collectively sold around 4.6% of their stake in Ajanta Pharma through a block deal, as reported by The Economic Times. This background indicates that the promoter group has used block deals earlier as a route for stake dilution or monetisation, with domestic market participants typically taking the other side.

Market impact and what investors will watch

From the reported numbers, the immediate market impact was twofold: promoter-linked selling was met with visible institutional buying, and the stock traded higher on the day at the quoted time stamps. The key near-term monitorable item for investors is the updated shareholding disclosures that follow such transactions, including the promoter and promoter-group classification in the subsequent filings. Investors will also track whether there are further block deals from promoter-linked entities and how mutual funds adjust their positions after the large single-day inflow. Separately, any changes in pledged shares within the promoter group, when disclosed, can be watched for their implications on promoter-level leverage.

Conclusion

Ajanta Pharma’s June 9, 2026 block deal moved about 34.5 lakh shares from a promoter-linked trust to two large domestic mutual funds at ₹2,968 per share, valuing the trade at roughly ₹1,024 crore. The trust’s stake fell from 13.00% to 10.24%, while the stock traded higher intraday after the transaction. The next set of exchange filings and shareholding updates will provide the cleanest view of how the post-deal ownership profile settles across promoter entities and institutions.